By Dr. Asnat Raziel, bariatric surgeon specializing in obesity treatment, metabolic health and healthy longevity; Director of the Multidisciplinary Center for Obesity Treatment, Assia Medical, Assuta Ramat HaChayal, Tel Aviv
Alzheimer’s and obesity: what we know today
Alzheimer’s and obesity may seem like two separate worlds, one in the brain and the other on the scale. But research shows a clear link between them, especially when obesity appears in midlife. The good news is that part of the risk of dementia depends on factors we can change. In this article I explain what is known about the connection, what is still unknown, and what you can do right now.
Alzheimer’s disease is the most common cause of dementia, meaning a progressive decline in memory and function. The disease develops silently for many years before symptoms appear. That is why our habits between the ages of 40 and 60 matter so much.
What studies show about Alzheimer’s and obesity
A systematic review and meta-analysis of 21 longitudinal studies examined the link between weight and dementia. The researchers found that obesity before age 65 was associated with a 41% higher risk of developing dementia later on. After age 65, however, the picture flipped: higher weight was associated with a slightly lower risk.
How do we explain this gap? In older adults, unintentional weight loss is sometimes an early sign of the disease itself. In other words, the disease lowers the weight, not the other way around. The practical message is therefore clear: it is weight in midlife that shapes the risk.
In addition, the expert commission of The Lancet published a comprehensive report on dementia prevention. The commission identified 14 modifiable risk factors, and obesity as a risk factor is one of them. By its estimate, addressing all of these factors together could prevent or delay up to 45% of dementia cases.
The link between Alzheimer’s and obesity: the mechanisms
The link between Alzheimer’s and obesity is not direct. It runs through several mechanisms that influence one another.
Insulin resistance and diabetes
First, obesity increases the risk of insulin resistance and type 2 diabetes. The brain also uses insulin, and insulin resistance impairs its ability to use energy. Diabetes, incidentally, appears on the commission’s list of risk factors in its own right.
Blood vessels and blood pressure
Second, obesity raises blood pressure and blood lipid levels. These damage the small blood vessels in the brain and reduce its blood supply. High blood pressure and high LDL cholesterol in midlife are also among the risk factors for dementia.
Chronic inflammation
In addition, excess fat tissue, especially abdominal fat, releases inflammatory substances. Chronic low-grade inflammation may also affect brain tissue.
Sleep and sleep apnea
Finally, obesity increases the risk of sleep apnea. Deep sleep is important for clearing waste from the brain, so fragmented sleep may harm it over the years.
Alzheimer’s and obesity: what you can do
There is no way to guarantee we will not get sick. Still, losing weight and improving metabolic health address several risk factors at once. Here are the main steps:
- Regular physical activity: it improves the body’s insulin sensitivity and blood flow to the brain.
- A Mediterranean diet: vegetables, legumes, fish and olive oil, with little processed food.
- Controlling blood pressure, blood sugar and cholesterol: regular checkups and treatment as needed.
- Good sleep: diagnosis and treatment of sleep apnea if you snore and feel tired in the morning.
- Social connection and mental activity: both protect the brain over the years.
It is important to remember that dramatic weight loss is not necessary. Even losing 5% to 10% of body weight improves blood sugar and blood pressure. At the clinic, we see that patients who stick with small changes gain health benefits for years. The change that matters is the one that lasts.
When diet and exercise are not enough, there are also options today for treating obesity with medication.
Alzheimer’s and obesity: what we learned about GLP-1 drugs
Observational studies hinted that patients taking GLP-1 medications develop dementia less often. Novo Nordisk therefore tested oral semaglutide in people with Alzheimer’s disease. The two large trials, EVOKE and EVOKE+, included 3,808 participants at an early stage of the disease.
However, the results presented in December 2025 were disappointing. The drug did not slow disease progression compared with placebo. In other words, at this stage there is no justification for giving GLP-1 medications as a treatment for Alzheimer’s. On the other hand, whether treating obesity in midlife reduces future risk is still an open question.
Planning ahead as a family
A diagnosis of dementia affects the whole family. That is why it is worth thinking ahead about the practical side too: who will make decisions, how finances will be managed, and what the person themselves wants. Some families seek legal advice about a lasting power of attorney. Planning like this, while memory is still intact, spares a great deal of stress later on.
The bottom line
The link between Alzheimer’s and obesity is real, but it is not destiny. Obesity in midlife raises the risk of dementia, mainly through diabetes, high blood pressure, inflammation and poor sleep. Treating these factors is good for the heart, the blood vessels and the brain. GLP-1 medications, by contrast, have not been proven as a treatment for Alzheimer’s itself. If you are between 40 and 60 and carrying excess weight, now is a good time to start.
The information in this article is general and does not replace personal medical advice.
Questions and answers
Does obesity cause Alzheimer’s?
Not directly. Obesity in midlife raises the risk, but Alzheimer’s results from a combination of genetics, age and lifestyle factors.
What is the link between Alzheimer’s and obesity in older age?
After age 65, the link is reversed: unexplained weight loss may be an early sign of the disease. In that case, it is worth seeing a doctor.
Does losing weight protect the brain?
Weight loss improves blood sugar, blood pressure and inflammation, all of which are risk factors for dementia. However, no trial has yet directly proven that it prevents Alzheimer’s.
Do weight loss drugs treat Alzheimer’s?
No. In the EVOKE trials, oral semaglutide did not slow the disease in patients at an early stage.
Sources
Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission
Results of EVOKE and EVOKE+ trials show no effect of oral semaglutide on AD progression
2024 Lancet Commission underscores the potential for dementia risk reduction
